Page last updated: 2024-12-09

2-(3-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-4h-quinoxalin-2-yl)-n-phenyl-acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

**2-(3-Oxo-1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydroquinoxalin-2-yl)-N-phenyl-acetamide** is a complex organic compound with a long and descriptive name. It's important to break it down to understand its potential significance in research.

**Structure and Features:**

* **Quinoxaline core:** The compound contains a quinoxaline ring system, which is a heterocyclic structure with two nitrogen atoms.
* **Sulfonyl group:** A toluene-4-sulfonyl group (Ts) is attached to one of the nitrogen atoms. This group can influence the molecule's reactivity and make it suitable for certain types of reactions.
* **Acyl group:** The compound has an acyl group (-CO-NH-) connected to the quinoxaline ring, specifically an N-phenyl-acetamide group. This group can be involved in interactions with other molecules, potentially leading to biological activity.

**Potential Research Significance:**

Without specific research contexts, it's difficult to pinpoint the exact importance of this compound. However, based on its structure, it could be relevant to various research areas:

* **Drug discovery:** The presence of the quinoxaline core and the N-phenyl-acetamide group suggests that this compound might exhibit biological activity and could be a potential candidate for drug development. The sulfonyl group might further enhance its biological properties.
* **Organic synthesis:** This compound could be an intermediate or starting material in various organic synthetic pathways. Its structure with functional groups allows for reactions that introduce new functionalities or modifications.
* **Materials science:** The rigid structure and potential for modifications could make this compound useful in developing new materials with specific optical, electrical, or mechanical properties.
* **Analytical chemistry:** The compound's unique properties could be used to develop new analytical techniques or sensors for detecting specific molecules or analytes.

**Further Research:**

To understand the real importance of this compound, further research is needed. This might involve:

* **Biological studies:** Testing its effects on different biological systems, such as cells or organisms.
* **Chemical synthesis:** Optimizing its synthesis and exploring modifications of its structure.
* **Applications in different fields:** Investigating its potential applications in materials science, analytical chemistry, or other disciplines.

**Important Note:** The exact role and importance of this compound will depend on the specific research context and the aims of the scientists involved.

2-(3-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-4H-quinoxalin-2-yl)-N-phenyl-acetamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID653087
CHEMBL ID1496953
SCHEMBL ID6403536
MeSH IDM0499555

Synonyms (12)

Synonym
EU-0034949
2-[3-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinoxalin-2-yl]-n-phenyl-acetamide
OPREA1_317074
OPREA1_226221
smr000009188
MLS000029444
2-[1-(4-methylphenyl)sulfonyl-3-oxo-2,4-dihydroquinoxalin-2-yl]-n-phenylacetamide
AKOS001603360
HMS2289D10
CHEMBL1496953
SCHEMBL6403536
2-(3-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-4h-quinoxalin-2-yl)-n-phenyl-acetamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency100.00000.531815.435837.6858AID504845
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720580
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency70.79460.354828.065989.1251AID504847
DNA polymerase betaHomo sapiens (human)Potency0.08910.022421.010289.1251AID485314
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.38720.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]